SeaCrest Wealth Management LLC increased its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 8.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,521 shares of the medical equipment provider’s stock after purchasing an additional 280 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Zimmer Biomet were worth $527,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Amundi Pioneer Asset Management Inc. boosted its position in Zimmer Biomet by 1.3% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 117,666 shares of the medical equipment provider’s stock worth $15,025,000 after acquiring an additional 1,465 shares during the period. Mackenzie Financial Corp grew its stake in Zimmer Biomet by 4.0% during the 2nd quarter. Mackenzie Financial Corp now owns 541,767 shares of the medical equipment provider’s stock valued at $63,788,000 after acquiring an additional 20,748 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Zimmer Biomet by 10.4% in the 2nd quarter. AQR Capital Management LLC now owns 187,007 shares of the medical equipment provider’s stock valued at $21,506,000 after purchasing an additional 17,540 shares during the period. Morgan Stanley increased its holdings in shares of Zimmer Biomet by 23.5% in the 2nd quarter. Morgan Stanley now owns 646,986 shares of the medical equipment provider’s stock valued at $76,176,000 after purchasing an additional 123,087 shares during the period. Finally, CSat Investment Advisory L.P. increased its holdings in shares of Zimmer Biomet by 240.0% in the 2nd quarter. CSat Investment Advisory L.P. now owns 323 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 228 shares during the period. 87.41% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently weighed in on the company. Deutsche Bank assumed coverage on Zimmer Biomet in a report on Friday, January 3rd. They issued a “hold” rating and a $108.00 target price on the stock. Needham & Company LLC upped their target price on Zimmer Biomet from $170.00 to $187.00 and gave the company a “strong-buy” rating in a report on Thursday, December 19th. Citigroup upgraded Zimmer Biomet from a “neutral” rating to a “buy” rating in a report on Thursday, January 2nd. SunTrust Banks assumed coverage on Zimmer Biomet in a report on Tuesday, January 7th. They issued a “buy” rating and a $179.00 target price on the stock. Finally, Zacks Investment Research upgraded Zimmer Biomet from a “sell” rating to a “hold” rating and set a $149.00 target price on the stock in a report on Sunday, November 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. Zimmer Biomet presently has an average rating of “Buy” and an average price target of $154.35.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.02. Zimmer Biomet had a positive return on equity of 13.71% and a negative net margin of 1.14%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the business earned $1.63 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. On average, analysts forecast that Zimmer Biomet Holdings Inc will post 7.83 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Thursday, December 26th. Zimmer Biomet’s payout ratio is 12.57%.
In related news, insider Aure Bruneau sold 15,171 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $146.78, for a total transaction of $2,226,799.38. 0.72% of the stock is currently owned by corporate insiders.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Recommended Story: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.